Printer Friendly

Invitrogen Launches Integrated Services Platform to Build the Human ORFeome; ORFeome BioCharter Program Bridges Genomics and Proteomics.

Business Editors & Health/Medical Writers

BIOWIRE2K

Invitrogen Corp. (Nasdaq:IVGN) today announced the launch of the ORFeome BioCharter(TM) Program.

Created primarily for pharmaceutical and biotechnology companies, the ORFeome BioCharter Program is a subscription-based service platform that provides member scientists tools they need to advance drug discovery research.

"Our goal is to build the human ORFeome, a collection of human ORFs (Open Reading Frames) cloned into a system that facilitates functional analysis," remarked Lyle Turner, president, chairman, and CEO of Invitrogen Corp. "ORFs have increasingly become the format of choice for studying genes and proteins and their role in specific diseases or pathways. ORFs include only the portion of the gene that encodes protein. This makes them more versatile than full-length genes, which contain extra regulatory sequences that can affect protein expression. By creating a representative ORF clone for every human gene, we can offer a lasting resource of genomic and proteomic information and a valuable standard in the industry."

To create the most value for drug discovery researchers, scientists who subscribe to the ORFeome BioCharter Program can help prioritize the building of specific clones to add to the ORF collection, thereby driving the content that will best suit their needs. BioCharter subscribers will also have regular conferences with Invitrogen R&D staff, preferred pricing on services, and early access to Invitrogen technologies.

To add further value, all ORF clones will be constructed in Invitrogen's Gateway(TM) platform, an advanced technology that can shuttle genes into a variety of different host organisms for comprehensive analysis of the encoded proteins. In addition, the DNA sequence of each clone will be independently verified to ensure the quality of the collection. "With sequence-verified ORFs in the Gateway platform, BioCharter partners will have significant advantages in their R&D efforts," remarked John Carrino, vice president of R&D at Invitrogen. "Gateway uses a simple, one-hour incubation step to accomplish what takes days using traditional research methods. By providing high-quality ORFs in the flexible Gateway platform, we believe we can accelerate drug discovery for our partners."

The BioCharter Program is part of Invitrogen's integrated platform that bridges genomic and proteomic research. "We work very closely with our customers to provide them with a suite of products and services for drug discovery," remarked Carrino. "As the BioCharter Program gains acceptance, we plan to expand the program to our academic and non-profit customers."

About Invitrogen

Invitrogen provides essential technologies to biotechnology and biopharmaceutical researchers and companies worldwide. The company manufactures and markets a breadth of products and services for life sciences discovery, development and production. These include research tools in kit form and catalog and custom products and services for corporate, academic and government entities. The company also engages in technology licensing, research services, large-scale production, and life science technical expertise and support. With operations in more than 20 countries and distributor relationships in 40 more, the company employs approximately 2700 people at its worldwide locations.

For more information about Invitrogen visit the Web site at www.invitrogen.com.

Certain statements contained in this press release are considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, and it is Invitrogen's intent that such statements be protected by the safe harbor created thereby. Such statements include, but are not limited to, statements relating to: 1) providing tools and/or services to advance, accelerate, or simplify drug discovery research; 2) creating a lasting genomic and proteomic information resource and/or a standard in the industry; 3) providing significant advantages to BioCharter partners through the Gateway ORF clone resource; and 4) plans to extend the BioCharter Program to academic and non-profit customers. Such forward-looking statements are subject to a number of risks, uncertainties and other factors that could cause actual results to differ materially from future results expressed or implied by such forward-looking statements. Potential risks and uncertainties include, but are not limited to: a) the extent to which researchers adopt the use of the human ORF collection in their drug discovery research; b) Invitrogen's ability to build the human ORFeome collection; c) the degree to which the human ORFeome collection suits researcher's needs; and d) whether Invitrogen can find mutually agreeable terms with potential BioCharter(TM) partners, as well as other risks and uncertainties detailed from time to time in Invitrogen's Securities and Exchange Commission filings.
COPYRIGHT 2002 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jun 25, 2002
Words:723
Previous Article:Fitch Rates $18.5MM King County Hsg Auth, Washington VRDBs 2002 'AA/F1+'.
Next Article:Fitch Ratings Upgrs $650MM Covanta Solid Waste Bonds.


Related Articles
MDS PROTEOMICS & ABGENIX DEVELOP ANTIBODY THERAPIES.
RHeoGene and Invitrogen Sign Licensing Agreement for Ecdysone Receptor Technology.
Invitrogen Acquires Product Lines and Technology Rights from Genicon Sciences; Purchase Includes Ultra-Sensitive Detection Platform for Life Science...
Invitrogen Bolsters Leading Position in RNAi Research; New Systems Add to Superior Delivery Technologies and Offer Total Solution.
ADVISORY/Invitrogen to Unveil Evolution of Gateway Technology at Society for Neuroscience Annual Meeting.
REMINDER/Invitrogen to Unveil Evolution of Gateway Technology at Society for Neuroscience Annual Meeting.
Invitrogen Corporation Acquires Protometrix, Inc.; Breakthrough Protein Microarray Technology to Offer Benchtop Access to the Human Proteome.
Norman J.W. Russell, Ph.D., Joins Invitrogen Corporation as Vice President and General Manager of Functional Genomics.
Invitrogen Signs Agreement with Nonlinear Dynamics to Distribute Advanced Analysis Software Solutions.
Invitrogen and the Human Proteome Organisation Enter Protein Research Scientific Partnership; Groups Will Further HUPO Scientific Initiatives, Enable...

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters